<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04505631</url>
  </required_header>
  <id_info>
    <org_study_id>GHR 1052</org_study_id>
    <secondary_id>IDRCB 2020-A01089-30</secondary_id>
    <nct_id>NCT04505631</nct_id>
  </id_info>
  <brief_title>Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19</brief_title>
  <acronym>SISCOVID</acronym>
  <official_title>Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier de la Region de Mulhouse et Sud Alsace</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier de la Region de Mulhouse et Sud Alsace</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this multicenter observational study is to describe respiratory sequelae of&#xD;
      COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized&#xD;
      patients with severe pneumonia requiring oxygen supply and followed up for 6 months after&#xD;
      hospital discharge (see primary and secondary outcomes).&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
      To describe pulmonary sequelae according to :&#xD;
&#xD;
        -  the unit in which the patient was hospitalized,&#xD;
&#xD;
        -  the maximum oxygen flow rate required during hospitalization,&#xD;
&#xD;
        -  McCabe score,&#xD;
&#xD;
        -  age,&#xD;
&#xD;
        -  tobacco consumption,&#xD;
&#xD;
        -  biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin),&#xD;
&#xD;
        -  number of days from onset of symptoms to hospitalization,&#xD;
&#xD;
        -  co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild&#xD;
           to moderate COPD/respiratory failure, overweight),&#xD;
&#xD;
        -  concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids,&#xD;
           immunosuppressants, ACE inhibitors)&#xD;
&#xD;
        -  specific drug treatments administered to treat COVID-19 infection,&#xD;
&#xD;
        -  non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment)&#xD;
           to manage respiratory disorders of COVID-19 infection.&#xD;
&#xD;
      To assess the impact of factors of social inequality on the severity of COVID-19 infection.&#xD;
&#xD;
      Conduct of research Patients who have been hospitalized for severe pneumonia due to CoV-2&#xD;
      SARS infection will be seen in consultation at approximately 3 and 6 months after hospital&#xD;
      discharge, as per standard practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Actual">January 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of respiratory sequelae</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>The presence of respiratory sequelae will be assessed by low dose thoracic tomodensitometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of respiratory sequelae on low dose thoracic tomodensitometry</measure>
    <time_frame>3 months after hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (FVC, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (FVC, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tiffeneau-Pinelli index (FEV1/FVC, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tiffeneau-Pinelli index (FEV1/FVC, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lung capacity (TLC, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lung capacity (TLC, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual volume (RV, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual volume (RV, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV/TLC ratio (%)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV/TLC ratio (%)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal inspiratory pressure (MIP, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal inspiratory pressure (MIP, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal expiratory pressure (MEP, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal expiratory pressure (MEP, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion capacity of the lungs for carbon monoxide (DLCO, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion capacity of the lungs for carbon monoxide (DLCO, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Respiratory functional exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen partial pressure (PaO2, mmHg)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen partial pressure (PaO2, mmHg)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial carbon dioxide partial pressure (PaCO2, mmHg)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial carbon dioxide partial pressure (PaCO2, mmHg)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bicarbonate concentration (mmol/L)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bicarbonate concentration (mmol/L)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen saturation (SaO2, %)</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen saturation (SaO2, %)</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Arterial gasometry will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute walk test</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Six-minute walk test will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute walk test</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Six-minute walk test will be performed under ambient air and under oxygen</description>
  </secondary_outcome>
  <enrollment type="Actual">332</enrollment>
  <condition>Covid19</condition>
  <condition>Dyspnea</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been hospitalized for severe pneumonia due to SARS-CoV-2 infection will&#xD;
        be seen in consultation at approximately 3 and 6 months after hospital discharge, as per&#xD;
        standard practice.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  SARS-CoV-2 infection proven by RT-PCR and/or retrospective serology and/or a COVID-19&#xD;
             syndrome with evocative chest CT scan&#xD;
&#xD;
          -  Hospitalized for severe pneumonia due to SARS-CoV-2 infection requiring oxygen supply&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Not hospitalized for a severe COVID-19 infection&#xD;
&#xD;
          -  Absence of respiratory symptoms at V1 (3 months after hospital discharge), defined as:&#xD;
             absence of residual exertional dyspnea and persistent pulmonary infiltrates on&#xD;
             follow-up chest radiography at 1 month (if available), transcutaneous oxyhemoglobin&#xD;
             saturation &gt;94% and normal pulmonary auscultation&#xD;
&#xD;
          -  Patient with pre-existing chronic lung disease prior to the first episode of COVID-19:&#xD;
             chronic obstructive pulmonary disease confirmed by respiratory function testing with a&#xD;
             forced expiratory volume in one second (FEV1) &lt; 50% and/or a diffusing capacity for&#xD;
             carbon monoxide (DLCO) &lt; 60%, fibrotic lung disease or chronic respiratory failure (on&#xD;
             long-term oxygen therapy)&#xD;
&#xD;
          -  Opposition to participation in the study&#xD;
&#xD;
          -  Patient under legal protection&#xD;
&#xD;
          -  Patient not affiliated to/beneficiary of a social security scheme&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George-Daniel Calcaianu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHRMSA hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier de Mulhouse et de la Région Sud-Alsace</name>
      <address>
        <city>Mulhouse</city>
        <state>Alsace</state>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque - Bayonne</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Métropole Savoie</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Douai</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Vendée - La Roche sur Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Robert Boulin - Libourne</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Metz-Tessy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Metz-Thioville</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Raincy Montfermeil</name>
      <address>
        <city>Montfermeil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Soissons</name>
      <address>
        <city>Soissons</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>PNEUMOPATHY</keyword>
  <keyword>DYSPNEA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04505631
org study id: GHR 1052
secondary id: IDRCB 2020-A01089-30
nct id: NCT04505631
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The objective of this multicenter observational study is to describe respiratory sequelae of
      COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.
Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized
      patients with severe pneumonia requiring oxygen supply and followed up for 6 months after
      hospital discharge (see primary and secondary outcomes).

      Secondary objectives

      To describe pulmonary sequelae according to :

        -  the unit in which the patient was hospitalized,

        -  the maximum oxygen flow rate required during hospitalization,

        -  McCabe score,

        -  age,

        -  tobacco consumption,

        -  biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin),

        -  number of days from onset of symptoms to hospitalization,

        -  co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild
           to moderate COPD/respiratory failure, overweight),

        -  concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids,
           immunosuppressants, ACE inhibitors)

        -  specific drug treatments administered to treat COVID-19 infection,

        -  non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment)
           to manage respiratory disorders of COVID-19 infection.

      To assess the impact of factors of social inequality on the severity of COVID-19 infection.

      Conduct of research Patients who have been hospitalized for severe pneumonia due to CoV-2
      SARS infection will be seen in consultation at approximately 3 and 6 months after hospital
      discharge, as per standard practice.
observational model: Cohort
time perspective: Prospective
measure: Presence of respiratory sequelae
time frame: 6 months after hospital discharge
description: The presence of respiratory sequelae will be assessed by low dose thoracic tomodensitometry
measure: Presence of respiratory sequelae on low dose thoracic tomodensitometry
time frame: 3 months after hospital discharge
measure: Forced vital capacity (FVC, %)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: Forced vital capacity (FVC, %)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: Forced expiratory volume in 1 second (FEV1, %)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: Forced expiratory volume in 1 second (FEV1, %)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: Tiffeneau-Pinelli index (FEV1/FVC, %)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: Tiffeneau-Pinelli index (FEV1/FVC, %)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: Total lung capacity (TLC, %)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: Total lung capacity (TLC, %)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: Residual volume (RV, %)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: Residual volume (RV, %)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: RV/TLC ratio (%)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: RV/TLC ratio (%)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: Maximal inspiratory pressure (MIP, %)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: Maximal inspiratory pressure (MIP, %)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: Maximal expiratory pressure (MEP, %)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: Maximal expiratory pressure (MEP, %)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %)
time frame: 6 months after hospital discharge
description: Respiratory functional exploration
measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %)
time frame: 3 months after hospital discharge
description: Respiratory functional exploration
measure: pH
time frame: 6 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: pH
time frame: 3 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Arterial oxygen partial pressure (PaO2, mmHg)
time frame: 6 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Arterial oxygen partial pressure (PaO2, mmHg)
time frame: 3 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg)
time frame: 6 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg)
time frame: 3 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Bicarbonate concentration (mmol/L)
time frame: 6 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Bicarbonate concentration (mmol/L)
time frame: 3 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Arterial oxygen saturation (SaO2, %)
time frame: 6 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Arterial oxygen saturation (SaO2, %)
time frame: 3 months after hospital discharge
description: Arterial gasometry will be performed under ambient air and under oxygen
measure: Six-minute walk test
time frame: 6 months after hospital discharge
description: Six-minute walk test will be performed under ambient air and under oxygen
measure: Six-minute walk test
time frame: 3 months after hospital discharge
description: Six-minute walk test will be performed under ambient air and under oxygen
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: George-Daniel Calcaianu, MD
role: Principal Investigator
affiliation: GHRMSA hospital
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
responsible party type: Sponsor
mesh term: COVID-19
mesh term: Dyspnea
sharing ipd: No